Siam Oottamasathien, MD
- Pediatric Urology Basic Science
- Bladder Inflammation and Fibrosis
- Developing Novel Hyaluronic Acid Based Biomaterials as Anti-Inflammatory Therapeutics
- Pioneering Animal Models for Investigating Bladder Inflammation
- Developing Therapeutics to Treat Interstitial Cystitis/Painful Bladder Syndrome
- Departments: Pharmaceutics and Pharmaceutical Chemistry - Adjunct Associate Professor, Surgery - Adjunct Associate Professor
- Divisions: Urology
Academic Office Information
Primary Children's Hospital
100 N Mario Capecchi Drive, Room: Suite 3550
Salt Lake City, UT 84113
Siam Oottamasathien, MD, FAAP, FACS is a board-certified urologist with subspecialty certification in pediatric urology. He attended the University of Colorado at Boulder studying Molecular Biology and Biochemistry, then obtained his medical degree and completed his urologic residency at the University of Colorado Health Sciences Center. Dr. Oottamasathien pursued a fellowship in pediatric urology at Vanderbilt University, with a special focus on basic science research and inflammatory disorders that affect the bladder. Currently, Dr. Oottamasathien’s practice is dedicated to pediatric urology but he also directs the basic science research efforts for the group. He is a member of multiple medical organizations, including the American Urological Association, Society for Basic Urologic Research, Society for Fetal Urology, and Society for Pediatric Urology. In addition, Dr. Oottamasathien is a Fellow of the American Academy of Pediatrics and Fellow of the American College of Surgeons.
Research StatementDr. Oottamasathien launched a pediatric urology basic science research program for the group in 2007. His initial work was in the Department of Human Molecular Biology and Genetics at the University of Utah, investigating the role of T-box proteins in genitourinary development. During that time, he gained invaluable research tools, developed elaborate experimental designs, including the use of germ-line and conditional mutagenesis experiments in mice, and further enhanced his background in genitourinary embryology, molecular biology, and developmental biology. In addition, he was awarded a three year NIH T32 training grant (5T32HL079874) under the auspices of Nobel Laureate Dr. Mario Capecchi and received NIH loan repayment program (LRP) funding for pediatric research. After spending a year and a half along this line of research, more clinical translational science was necessary and he partnered with the laboratory of Glenn Prestwich, PhD, a senior investigator and presidential professor of medicinal chemistry at the University of Utah.
Since establishing his collaboration with Dr. Prestwich, his projects have demonstrated great potential in making a significant impact towards treating pediatric urologic disease conditions. The scientific aspects build upon novel hyaluronic acid (HA)—based biomaterials and have been used to investigate and treat bladder inflammatory and fibrotic conditions. Thus far, he has obtained grant funding from the National Kidney Foundation—Utah Chapter, Early Career Development Award from the Primary Children’s Hospital Foundation, NIH K12 Career Development Award (UL1RR025764) University of Utah Center for Clinical and Translational Science, American Urological Association/Pfizer Award for Investigation in Benign Urologic Disease, Primary Children’s Hospital Integrated Science Award, and an NIH Phase I SBIR Grant (R43DK093413) in conjunction with a small start up company GlycoMira Therapeutics that Dr. Oottamasathien is a part of. Recently, Dr. Oottamasathien received NIH R01 funding to further investigate the treatment of bladder pain by novel glycosaminoglycan derivatives (R01DK100868). Dr. Oottamasathien has also been a three-time recipient (2006, 2010, 2012) of the prestigious Basic Science Research Award presented by the American Academy of Pediatrics Section on Urology. He was also selected in 2013 by the Society of Pediatric Urology as their early career investigator representative and presented his group’s work at the 2013 American Urologic Association Annual Meeting showcasing the best of the best early career investigators. At this forum, he was awarded 2nd place honors. His research efforts continue to represent significant, innovative, and high-impact science that continues to move the field of urology forward.
|Chief Resident||University of Colorado at Denver and Health Sciences Center
|Residency||University of Colorado at Denver and Health Sciences Center
|Residency||University of Colorado at Denver and Health Sciences Center
|Internship||University of Colorado at Denver and Health Sciences Center
|Professional Medical||University of Colorado School of Medicine
|Undergraduate||University of Colorado at Boulder
Double Major: Molecular Biology and Biochemistry
|Undergraduate||Illinois Institute of Technology
- Gabrielsen JS, Laciak RJ, Frank EL, McFadden M, Bates CS, Oottamasathien S, Hamilton BD, Wallis MC (2012). Pediatric urinary stone composition in the United States. J Urol, 187(6), 2182-7.
- Oottamasathien S, Jia W, McCoard L, Slack S, Zhang J, Skardal A, Job K, Kennedy TP, Dull RO, Prestwich GD (2011). A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. J Urol, 186(4 Suppl), 1684-92.
- Willis HL, Snow BW, Cartwright PC, Wallis MC, Oottamasathien S, deVries C (2011). Parameatal urethral cysts in prepubertal males. J Urol, 185(3), 1042-5.
- Skardal A, Zhang J, McCoard L, Oottamasathien S, Prestwich GD (2010). Dynamically crosslinked gold nanoparticle - hyaluronan hydrogels. Adv Mater, 22(42), 4736-40.
- Skardal A, Zhang J, McCoard L, Xu X, Oottamasathien S, Prestwich GD (2010). Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting. Tissue Eng Part A, 16(8), 2675-85.
- Wicher C, Hadley D, Ludlow D, Oottamasathien S, Wallis MC, Devries C, Snow BW, Cartwright PC (2010). 250 consecutive unilateral extravesical ureteral reimplantations in an outpatient setting. J Urol, 184(1), 311-4.
- Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC, Brock JW 3rd, Hayward SW, Matusik RJ, Pope JC 4th (2008). Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol, 180(4 Suppl), 1784-9.
- Matusik RJ, Jin RJ, Sun Q, Wang Y, Yu X, Gupta A, Nandana S, Case TC, Paul M, Mirosevich J, Oottamasathien S, Thomas J (2008). Prostate epithelial cell fate. Differentiation, 76(6), 682-98.
- Oottamasathien S, Williams K, Franco OE, Wills ML, Thomas JC, Sharif-Afshar AR, DeMarco RT, Brock JW 3rd, Bhowmick NA, Hayward SW, Pope JC 4th (2007). Urothelial inhibition of transforming growth factor-beta in a bladder tissue recombination model. J Urol, 178(4 Pt 2), 1643-9.
- Oottamasathien S, Thomas JC, Adams MC, DeMarco RT, Brock JW 3rd, Pope JC 4th (2007). Testicular tumours in children: a single-institutional experience. BJU Int, 99(5), 1123-6.
- Oottamasathien S, Wang Y, Williams K, Franco OE, Wills ML, Thomas JC, Saba K, Sharif-Afshar AR, Makari JH, Bhowmick NA, DeMarco RT, Hipkens S, Magnuson M, Brock JW 3rd, Hayward SW, Pope JC 4th, Matusik RJ (2007). Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol, 304(2), 556-66.
- Oottamasathien S, Thomas JC, Adams MC, Demarco RT, Brock JW 3rd, Pope JC 4th (2007). Testicular tumours in children: a single-institutional experience. (Epub ahead of print) BJU Int.
- Oottamasathien S, Williams K, Franco OE, Thomas JC, Saba K, Bhowmick NA, Staack A, Demarco RT, Brock JW 3rd, Hayward SW, Pope JC 4th (2006). Bladder tissue formation from cultured bladder urothelium. Dev Dyn, 235(10), 2795-801.
- Brant WO, Rajimwale A, Lovell MA, Travers SH, Furness PD 3rd, Sorensen M, Oottamasathien S, Koyle MA (2006). Gonadoblastoma and Turner syndrome. J Urol, 175(5), 1858-60.
- Oottamasathien S, Snow BW (2011). Office Procedures for Pediatric Urology. In AUA Update Series (Lesson 31, v. 30). American Urologic Association.
- Oottamasathien S, Furness PD, Mingin G, Brant WO, Koyle MA (2006). Management of Undescended Testes. Progress in Paediatric Urology Volume 8. New Delhi, London and Washington: Penwel Publishers PLC.
- Oottamasathien S, Wills ML, Brock JW 3rd, Pope JC 4th (2007). Primary extrarenal nephroblastomatosis. Urology, 69(1), 184.e3-4.
- Pohl JF, Comstock JM, Oottamasathien S (2011). Metastatic Crohn's disease of the penis in a pediatric patient. [Letter to the editor]. Inflamm Bowel Dis, 17(4), 1056.
- Oottamasathien S, Jia W, Roundy LM, Zhang J, Wang L, Ye X, Hill AC, Savage J, Lee WY, Hannon A, Milner S, Prestwich GD (2012). Physiologic Relevance of LL-37 Induced Bladder Inflammation and Mast Cells [Abstract]. American Academy of Pediatrics National Conference and Exhibition, New Orleans, LA.
- Jia WJ, McCoard L, Zhang J, Skardal A, Prestwich GD, Oottamasathien S (2010). Abrogaton of LL-37 Mediated Bladder Inflammation and the Role of the Receptor for Advanced Glycation End-Products (RAGE) Pathway [Abstract]. Western Section American Urological Association Annual Meeting, Waikoloa, HI.
- Gabrielsen JS, Laciak RJ, Frank EL, McFadden M, Bates CS, Oottamasathien S, Hamilton BD, Wallis MC (2010). Pediatric Urinary Stone Composition in the United States [Abstract]. Western Section American Urological Association Annual Meeting, Waikoloa, HI.
- Wicher CG, Hadley DA, Cartwright PC, Oottamasathien S (2009). Scrotoplasty in Scrotal Agenesis [Abstract]. American Urological Association Video Presentation.
- Foot LM, Bates CS, Steadman C, Laciak RJ, Oottamasathien S (2008). Testis Tumors in Children - An Argument for Testis Sparing Surgery [Abstract]. Western Section American Urological Association Annual Meeting, Monterey, CA.
- Wicher C, Hadley DA, Cartwright PC, Oottamasathien S (2008). Scrotoplasty in Scrotal Agenesis [Abstract]. Western Section American Urological Association Video Presentation.
- Oottamasathien S, Jia W, McCoard L, Prestwich GD (2013). SAGE Therapeutic: Methods for Treating and Preventing Urological Inflammation. U.S. Patent No. 8,343,942. Washington, D.C.:U.S. Patent and Trademark Office.